POST-ASCO 2019 GI Cancer Halfdan Sorbye Professor, MD Haukeland Univ Hospital Bergen, Norway
DISCLOSURES Consultant: Novartis, Pfizer, Keocyt, AstraZeneca. Honoraria: Ipsen, Novartis, Roche, Amgen, Merck, Shire, Celgene. Research funding: Novartis, Ipsen, Amgen. 2
Flere abstrakt på øvre GI 140 vs 110 på CRC Plenary øvre GI 3
Metastatic pancreatic cancer Presented By Hedy Kindler at 2019 ASCO Annual Meeting
Study design Presented By Hedy Kindler at 2019 ASCO Annual Meeting
Objective response* in patients with measurable disease <br />by blinded independent central review<br /> Presented By Hedy Kindler at 2019 ASCO Annual Meeting
Primary endpoint: PFS by blinded<br />independent central review* Presented By Hedy Kindler at 2019 ASCO Annual Meeting
OS: interim analysis, 46% maturity* Presented By Hedy Kindler at 2019 ASCO Annual Meeting
Gjennombrudd? Endelig en biomarkør for pancreas cancer NCCN i USA rutine BRAC testing på pancreas ca. Få pasienter (4%) aktuelle stort apperat. Unge? Skuffende gevinst PFS 3m, ingen OS. Men lang varighet av respons. Subopitimal kontroll arm vanligvis lengre behandling med FOLFIRINOX Kan bli en viktig del av en kombinasjonsbehandling 10
Abstract 4000 Presented By Margaret Tempero at 2019 ASCO Annual Meeting
Optimizing Chemotherapy for Frail and Elderly Patients with Advanced Gastroesophageal Cancer: Presented By Peter Hall at 2019 ASCO Annual Meeting
Slide 5 Arm A tilsvarer omtrent capecitabine 1000mg/2 x 2 dag 1-14. Presented By Peter Hall at 2019 ASCO Annual Meeting
Patients Presented By Peter Hall at 2019 ASCO Annual Meeting
Slide 12 Presented By Peter Hall at 2019 ASCO Annual Meeting
Slide 23 Pasient som vurderes til å ikke kunne tåle full dose- gå ned til 60% dose. Kan alle gis 60% dose? OS lavere enn i studier 7.6 vs 13.3 m (EJC 2012) Presented By Peter Hall at 2019 ASCO Annual Meeting
Slide 11
Pembrolizumab With or Without Chemotherapy Versus Chemotherapy in Advanced G/GEJ Adenocarcinoma: The Phase 3, KEYNOTE-062 Study Presented By Josep Tabernero at 2019 ASCO Annual Meeting
KEYNOTE-062 Study Design (NCT02494583) Presented By Josep Tabernero at 2019 ASCO Annual Meeting
21
Overall Survival: P+C vs C (CPS 1) Presented By Josep Tabernero at 2019 ASCO Annual Meeting
Overall Survival: P vs C (CPS 1) Presented By Josep Tabernero at 2019 ASCO Annual Meeting
USA Pembro standard 3-linje Pembro 1-linje til pasienter som ikke tåler kjemo CPS>10: pembro 1-linje en mulighet 24
Slide 13 Presented By Osama Rahma at 2019 ASCO Annual Meeting
Slide 15 Presented By Osama Rahma at 2019 ASCO Annual Meeting
Hva sier vi til våre metastatiske esofagus/ventrikkel pasienter om immunterapi? Skal de informeres aktivt eller kun når de spør? ca 10% ser ut til å ha en markant nytte. Foreløpig ikke tilbud i det offentlige helsevesen. Om de vil ha videre behandling- nok det beste. Selv med effekt privat- offentlige overtar ikke pga likhetsprinsippet. 27
Immunterapi og HCC Monoterapi ser ikke ut til å ha særlig effekt Overall Survival (OS)
Slide 18
Slide 20
Results: DFS Comparison by Regimen Presented By Timothy Iveson at 2019 ASCO Annual Meeting
Primary outcome results: 2-year efficacy
So what did we learn from FOxTROT? Neocol studien (NCT01918527) som er en fase III studie 250 pasienter med lokalavansert kolonkreft : 3 CAPOX før operasjon og postopr kjemo om indikasjon vs Standard 8 CAPOX etter operasjon
in metastatic colorectal cancer Should we escalate 1st-line therapy to FOLFOXIRI?
Slide 11
Slide 26
39
Slide 3 Dobbel immunblokkering (PD-L1 og CTLA-4) Presented By Joleen Hubbard at 2019 ASCO Annual Meeting
TMB predictive for OS: Presented By Joleen Hubbard at 2019 ASCO Annual Meeting
Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics (PK) and Efficacy of AMG 510, a Novel Small Molecule KRASG12C Inhibitor, in Advanced Solid Tumors
CRC and Other Solid Tumors: Best Tumor Response* (n=19)
CRC: Individual Patient Radiologic Response and Biomarkers
Studien som ikke rakk ASCO med 3 dager: Press : 22 MAY 2019 The phase III BEACON study BRAF V600E-mutant mcrc 2/3 line. BRAF-inh + MEK-inh + cetuximab vs irinotecan-combo + cetux. Significant improvement in RR and OS Triplet lowered the risk of death by 48% and mos 9 m. 45
REGONIVO: Safety and Activity